Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction.

Gulati G, Iffland PH 2nd, Janigro D, Zhang B, Luggen ME.

Clin Rheumatol. 2016 Dec;35(12):2989-2997. Epub 2016 Jun 29.

PMID:
27357716
2.

Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE.

Luggen ME, Gulati G, Zhang B, Willis RA, Gonzalez EB.

Clin Rheumatol. 2016 Jan;35(1):93-9. doi: 10.1007/s10067-015-3114-8. Epub 2015 Nov 12.

PMID:
26563139
3.

Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.

Genovese MC, Schiff M, Luggen M, Le Bars M, Aranda R, Elegbe A, Dougados M.

J Rheumatol. 2012 Aug;39(8):1546-54. doi: 10.3899/jrheum.111531. Epub 2012 Jul 15.

PMID:
22798265
4.

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study.

Keystone EC, Kremer JM, Russell A, Box J, Abud-Mendoza C, Elizondo MG, Luo A, Aranda R, Delaet I, Swanink R, Gujrathi S, Luggen M.

Ann Rheum Dis. 2012 Jun;71(6):857-61. doi: 10.1136/annrheumdis-2011-200355. Epub 2012 Feb 2.

PMID:
22302417
5.

Cognitive dysfunction in SLE: development of a screening tool.

Adhikari T, Piatti A, Luggen M.

Lupus. 2011 Oct;20(11):1142-6. doi: 10.1177/0961203311405374. Epub 2011 Jun 15.

PMID:
21676920
6.

Cognitive dysfunction in patients with systemic lupus erythematosus: a controlled study.

Antonchak MA, Saoudian M, Khan AR, Brunner HI, Luggen ME.

J Rheumatol. 2011 Jun;38(6):1020-5. doi: 10.3899/jrheum.100560. Epub 2011 Apr 1.

PMID:
21459946
7.

Monitoring methotrexate toxicity in juvenile idiopathic arthritis.

Kocharla L, Taylor J, Weiler T, Ting TV, Luggen M, Brunner HI.

J Rheumatol. 2009 Dec;36(12):2813-8. doi: 10.3899/jrheum.090482. Epub 2009 Nov 16.

PMID:
19918032
8.

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M.

Ann Rheum Dis. 2008 Apr;67(4):547-54. Epub 2007 Oct 5.

PMID:
17921185
9.

Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.

Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM.

JAMA. 2007 Jul 11;298(2):187-93.

PMID:
17622600
10.
11.

Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration.

Ahmed M, Luggen M, Herman JH, Weiss KL, Decourten-Myers G, Quinlan JG, Khanna D.

J Rheumatol. 2006 Nov;33(11):2344-6. Epub 2006 Sep 15.

PMID:
16981287
12.

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.

Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, Chen D, Becker JC.

Ann Rheum Dis. 2007 Feb;66(2):228-34. Epub 2006 Aug 25.

13.

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M.

N Engl J Med. 2005 Sep 15;353(11):1114-23. Erratum in: N Engl J Med. 2005 Nov 24;353(21):2311.

14.

Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.

Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, Weisman M, Waltuck J, Lindsley HB, Markenson J, Crawford B, Fernando I, Simpson K, Strand V.

J Rheumatol. 2004 Aug;31(8):1521-31.

PMID:
15290730
15.

Trials are short, disease long: measuring drug utility beyond clinical trials.

Luggen ML.

J Rheumatol. 2004 Feb;31(2):205-6. Review. No abstract available.

PMID:
14760785
16.

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.

Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson JA, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM.

Ann Intern Med. 2002 Nov 5;137(9):726-33.

PMID:
12416946
17.

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.

Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC.

Arthritis Rheum. 2002 Jun;46(6):1470-9.

18.

Treatment of rheumatic diseases in the elderly.

Luggen M.

Geriatr Nurs. 2001 May-Jun;22(3):118-9. No abstract available.

PMID:
11410761
19.

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.

Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME, Totoritis MC.

Clin Pharmacol Ther. 1999 Sep;66(3):246-57.

PMID:
10511060
20.

Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD.

Williams HJ, Alarcon GS, Joks R, Steen VD, Bulpitt K, Clegg DO, Ziminski CM, Luggen ME, St Clair EW, Willkens RF, Yarboro C, Morgan JG, Egger MJ, Ward JR.

J Rheumatol. 1999 Apr;26(4):816-25.

PMID:
10229402
22.

Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases.

Williams HJ, Alarcón GS, Neuner R, Steen VD, Bulpitt K, Clegg DO, Ziminski CM, Luggen ME, Polisson RP, Willkens RF, Yarboro C, Morgan J, Egger MJ, Ward JR.

J Rheumatol. 1998 Feb;25(2):261-8.

PMID:
9489817
23.

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study.

Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR Jr, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG.

Arthritis Rheum. 1996 Dec;39(12):2013-20.

PMID:
8961906
24.

Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study.

Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, Mahowald ML, Schumacher HR Jr, Taylor T, Budiman-Mak E, Cohen MR, Vasey FB, Luggen ME, Mejias E, Silverman SL, Makkena R, Alepa FP, Buxbaum J, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG.

Arthritis Rheum. 1996 Dec;39(12):2004-12.

PMID:
8961905
26.

The evolution of Raynaud's phenomenon: a longterm prospective study.

Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G.

J Rheumatol. 1995 Dec;22(12):2226-32.

PMID:
8835553
27.

[Duration of use of non-steroidal anti-inflammatory agents in patients with rheumatoid arthritis].

Luggen ME.

Rev Rhum Ed Fr. 1994 Dec 15;61(10 Pt 2):165S-172S. Review. French.

PMID:
7858568
28.

Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis).

Bulpitt KJ, Clements PJ, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS, Singer JZ, Steen VD, Clegg DO, Ziminski CM, Alarcon GS, Luggen ME, Polisson RP, Willkens RF, Reading JC, Williams HJ, Ward JR.

Ann Intern Med. 1993 Apr 15;118(8):602-9.

PMID:
8452326
29.

Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases.

Clegg DO, Williams HJ, Singer JZ, Steen VD, Schlegel S, Ziminski C, Alarcón GS, Luggen ME, Polisson RP, Willkens RF, et al.

J Rheumatol. 1991 Sep;18(9):1340-3.

PMID:
1757935
30.

Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease.

Alarcón GS, Williams GV, Singer JZ, Steen VD, Clegg DO, Paulus HE, Billingsley LM, Luggen ME, Polisson RP, Willkens RF, et al.

J Rheumatol. 1991 Sep;18(9):1332-9.

PMID:
1757934
31.

Prenatal screening for anticardiolipin antibody.

Bendon RW, Hayden LE, Hurtubise PE, Getahun B, Siddiqi TA, Glueck HI, Luggen ME, Gartside PS.

Am J Perinatol. 1990 Jul;7(3):245-50.

PMID:
2372331
32.

Nonsteroidal antiinflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value.

Luggen ME, Gartside PS, Hess EV.

J Rheumatol. 1989 Dec;16(12):1565-9.

PMID:
2625688
33.

Remodeling the pyramid--a concept whose time has not yet come.

Hess EV, Luggen ME.

J Rheumatol. 1989 Sep;16(9):1175-6. No abstract available.

PMID:
2572698
34.

Unusual longevity in primary systemic amyloidosis: a 19-year survivor.

Fritz DA, Luggen ME, Hess EV.

Am J Med. 1989 Feb;86(2):245-8. No abstract available.

PMID:
2913790
35.

A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis.

Williams HJ, Ward JR, Dahl SL, Clegg DO, Willkens RF, Oglesby T, Weisman MH, Schlegel S, Michaels RM, Luggen ME, et al.

Arthritis Rheum. 1988 Jun;31(6):702-13.

PMID:
2898244
36.

Morbidity from repetitive knee trauma in carpet and floor layers.

Thun M, Tanaka S, Smith AB, Halperin WE, Lee ST, Luggen ME, Hess EV.

Br J Ind Med. 1987 Sep;44(9):611-20.

37.

Lack of association between HLA-DR2 and clinical response to methotrexate in patients with rheumatoid arthritis.

Alarcón GS, Billingsley LM, Clegg DO, Hardin JG, Klippel J, Luggen ME, Polisson RP, Singer JZ, Szydlo L, Willkens RF, et al.

Arthritis Rheum. 1987 Feb;30(2):218-20.

PMID:
3548733
38.

Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.

Williams HJ, Willkens RF, Samuelson CO Jr, Alarcón GS, Guttadauria M, Yarboro C, Polisson RP, Weiner SR, Luggen ME, Billingsley LM, et al.

Arthritis Rheum. 1985 Jul;28(7):721-30.

PMID:
3893441
39.

Skin effects of occupational kneeling.

Tanaka S, Halperin WE, Smith AB, Lee ST, Luggen ME, Hess EV.

Am J Ind Med. 1985;8(4-5):341-9.

PMID:
4073031
40.

A computer model of the renal countercurrent system.

Stewart J, Luggen ME, Valtin H.

Kidney Int. 1972 Nov;2(5):253-63. No abstract available.

Supplemental Content

Loading ...
Support Center